Topic Highlight
Copyright ©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Dec 14, 2008; 14(46): 7068-7074
Published online Dec 14, 2008. doi: 10.3748/wjg.14.7068
Hepatic drug transporters and nuclear receptors: Regulation by therapeutic agents
Aldo D Mottino, Viviana A Catania
Aldo D Mottino, Viviana A Catania, Instituto de Fisiología Experimental, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 570 (S2002LRL)-Rosario, Argentina
Author contributions: Both authors contributed similarly to the manuscript.
Supported by Grants from Agencia Nacional de Promoción Científicay Tecnológica (PICT Nº 05-26306), Consejo Nacional de Investigaciones Científicasy Técnicas (PIP Nº 6442) and Universidad Nacional de Rosario, Argentina
Correspondence to: Aldo D Mottino, PhD, Instituto de Fisiología Experimental, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Suipacha 570 (S2002LRL)-Rosario, Argentina. amottino@unr.edu.ar
Telephone: +54-341-4305799 Fax: +54-341-4399473
Received: September 3, 2008
Revised: October 23, 2008
Accepted: October 30, 2008
Published online: December 14, 2008
Abstract

The canalicular membrane represents the excretory pole of hepatocytes. Bile is an important route of elimination of potentially toxic endo- and xenobiotics (including drugs and toxins), mediated by the major canalicular transporters: multidrug resistance protein 1 (MDR1, ABCB1), also known as P-glycoprotein, multidrug resistance-associated protein 2 (MRP2, ABCC2), and the breast cancer resistance protein (BCRP, ABCG2). Their activities depend on regulation of expression and proper localization at the canalicular membrane, as regulated by transcriptional and post-transcriptional events, respectively. At transcriptional level, specific nuclear receptors (NR)s modulated by ligands, co-activators and co-repressors, mediate the physiological requirements of these transporters. This complex system is also responsible for alterations occurring in specific liver pathologies. We briefly describe the major Class II NRs, pregnane X receptor (PXR) and constitutive androstane receptor (CAR), and their role in regulating expression of multidrug resistance proteins. Several therapeutic agents regulate the expression of relevant drug transporters through activation/inactivation of these NRs. We provide some representative examples of the action of therapeutic agents modulating liver drug transporters, which in addition, involve CAR or PXR as mediators.

Keywords: Drug transport, Biliary secretion, ABC proteins, Multidrug resistance proteins, Nuclear receptors, Constitutive androstane receptor, Pregnane X receptor, Therapeutic agents